ADC Therapeutics insider has 49,508 shares withheld for taxes

ADC Therapeutics SA reported an insider transaction by Chief Legal Officer Peter Graham.

Accepted by SEC EDGAR 12/09/2025 - 05:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ADC Therapeutics SA reported an insider transaction by Chief Legal Officer Peter Graham. On 12/06/2025, the company withheld 49,508 common shares at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this withholding, Graham beneficially owns 359,034 common shares directly. The filing notes that this is a routine tax withholding transaction rather than an open‑market sale, and no derivative securities transactions were reported.

Insider Trade Summary

Exercise Price or Tax Liability: 49,508 shares

Exercise Price or Tax Liability 1 txn

Insider GRAHAM PETER J

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Shares	49,508	$3.29	$163K

Holdings After Transaction: Common Shares — 359,034 shares (Direct)

Holdings Before and After: Common Shares, 408,542 to 359,034 shares (Direct)

Footnotes (1)

1. F1. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADC Therapeutics (ADCT) report in this filing?

The filing reports that Chief Legal Officer Peter Graham had 49,508 common shares withheld by ADC Therapeutics to satisfy tax withholding obligations related to the vesting of restricted share units.

Who is the reporting person in this ADC Therapeutics (ADCT) Form 4?

The reporting person is Peter Graham, who serves as an officer of ADC Therapeutics SA with the title of Chief Legal Officer.

What was the transaction date and price for the ADCT shares withheld?

The transaction occurred on 12/06/2025, and 49,508 common shares of ADC Therapeutics were withheld at a price of $3.29 per share to cover taxes.

How many ADC Therapeutics (ADCT) shares does Peter Graham own after this transaction?

Following the reported tax withholding transaction, Peter Graham beneficially owns 359,034 ADC Therapeutics common shares, held directly.

Was this ADC Therapeutics (ADCT) insider transaction an open-market sale?

No. The explanation states that the 49,508 common shares were withheld by the issuer solely to satisfy Peter Graham's tax withholding obligations tied to vesting restricted share units, not an open-market sale.

Does this ADC Therapeutics (ADCT) filing report any derivative securities activity?

The section for derivative securities is present, but no specific derivative securities transactions (such as options or warrants) are reported in the provided content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAHAM PETER J

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NJ 07974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/06/2025		F(1)		49,508	D(1)	$3.29	359,034	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, Attorney-in-Fact for Peter Graham	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.